

abbvie OnabotA X
2042-201-008 – Statistical Analysis Plan
Version 2.0 – 12 December 2022

Statistical Analysis Plan for Study 2042-201-008

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of OnabotulinumtoxinA X for the Treatment of Moderate to Severe Glabellar Lines

Date: 12 December 2022

Version 2.0

Table of Contents

1.0	Introduction	5
2.0	Study Design and Objectives	5
2.1	Objectives, Hypotheses and Estimands	5
2.2	Study Design Overview	6
2.3	Treatment Assignment and Blinding	7
2.4	Sample Size Determination.....	7
3.0	Endpoints.....	8
3.1	Primary Endpoint(s).....	8
3.2	Secondary Endpoint(s)	8
3.3	Other Efficacy Endpoint(s)	8
3.4	Safety Endpoint(s)	10
3.5	Additional Endpoint(s).....	11
4.0	Analysis Populations	11
5.0	Subject Disposition	12
6.0	Study Drug Duration and Compliance.....	12
7.0	Demographics, Baseline Characteristics, Medical History, and Prior/Concomitant Medications	12
7.1	Demographics and Baseline Characteristics	13
7.2	Medical History	13
7.3	Prior and Concomitant Medications	13
7.4	Concurrent Procedure	14
8.0	Handling of Potential Intercurrent Events for the Primary and Key Secondary Endpoints.....	14
9.0	Efficacy Analyses	15
9.1	General Considerations	15
9.2	Handling of Missing Data	15
9.3	Primary Efficacy Endpoint(s) and Analyses	17
9.3.1	Primary Efficacy Endpoint(s)	17
9.3.2	Main Analysis of Primary Efficacy Endpoint(s)	17
9.3.3	Sensitivity and Supplementary Analyses of the Primary Efficacy Endpoint(s).....	18

9.4	Secondary Efficacy Endpoints and Analyses	18
9.4.1	Key Secondary Efficacy Endpoints	18
9.4.2	Main Analyses of Key Secondary Efficacy Endpoints	19
9.4.3	Sensitivity and Supplementary Analyses for Key Secondary Efficacy Endpoints	21
9.4.4	Supportive Secondary Efficacy Endpoints and Analyses	21
9.5	Additional Efficacy Analyses	21
9.6	Efficacy Subgroup Analyses	23
10.0	Safety Analyses	23
10.1	General Considerations	23
10.2	Adverse Events	23
10.2.1	Treatment-Emergent Adverse Events	23
10.2.2	Adverse Event Overview	24
10.2.3	Treatment-Emergent Adverse Events by SOC and/or PT	24
10.2.4	SAEs (Including Deaths) and Adverse Events Leading to Study Drug Discontinuation	25
10.2.5	Potential Distant Spread of Toxin Adverse Events	25
10.3	Analysis of Laboratory Data	25
10.4	Analysis of Vital Signs	26
10.5	Safety Subgroup Analyses	27
10.6	Other Safety Analyses	27
11.0	Other Analyses	28
12.0	Interim Analyses	28
12.1	Data Monitoring Committee	29
13.0	Overall Type-I Error Control	29
14.0	Version History	30
15.0	References	30

List of Tables

Table 1.	Summary of the Estimand Attributes of the Primary Efficacy Endpoint	17
----------	---	----

Table 2.	Summary of the Estimand Attributes of the Secondary Efficacy Endpoints	20
Table 3.	SAP Version History Summary	30

List of Figures

Figure 1.	Study Schematic.....	7
-----------	----------------------	---

List of Appendices

Appendix A.	Protocol Deviations.....	31
Appendix B.	Definition of Possible Distant Spread of Toxin	32
Appendix C.	Potentially Clinically Important Criteria for Safety Endpoints	33

1.0 Introduction

This Statistical Analysis Plan (SAP) describes the statistical analyses for OnabotA X Study 2042-201-008 Glabellar Lines: OnabotulinumtoxinA X in the Treatment of Moderate to Severe Glabellar Lines.

Study 2042-201-008 examines the safety and efficacy of OnabotA X in subjects with moderate to severe glabellar lines.

The SAP will not be updated in case of administrative changes or amendments to the protocol unless the changes impact the analysis.

Unless noted otherwise, all analyses will be performed using SAS Version 9.4 (SAS Institute Inc., Cary, NC 27513) or later under the Linux operating system.

2.0 Study Design and Objectives

2.1 Objectives, Hypotheses and Estimands

The primary objectives of the study are to compare the efficacy of OnabotA X and placebo and to evaluate the safety of OnabotA X in subjects with moderate to severe GL.

The null and alternate hypotheses are the following:

$H_0: P_T = P_P$ (The treatment response probability between each OnabotA X treatment group and the placebo group is equal)

$H_A: P_T \neq P_P$ (The treatment response probability between each OnabotA X treatment group and the placebo group is not equal)

Estimand attributes of the primary efficacy endpoint are detailed in Table 1 (see Section 9.3.2). In addition, the attribute of treatment is a single dose of active treatment or placebo.

Differences in proportion of subjects who would achieve ≥ 1 -grade improvement from baseline on the investigator-rated AGLSS at maximum contraction at Day 30 had they not

missed AGLSS assessments, for each active treatment group (OnabotA X [REDACTED] [REDACTED]) in comparison with placebo in the ITT population.

Any missing assessments will be assumed to be missing at random and imputed using multiple imputation. Statistical significance of the difference will be tested using Cochran-Mantel-Haenszel (CMH) test stratified by baseline investigator-rated AGLSS at maximum contraction.


[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

The clinical hypothesis is that OnabotA X has an acceptable safety profile when administered to the corrugator and procerus muscles in subjects with moderate to severe GL.

No estimand is defined for the safety evaluations.

2.2 Study Design Overview


The schematic of the study is shown in Figure 1.

Figure 1. Study Schematic**2.3****Treatment Assignment and Blinding**

Subjects will be randomized in a 2:2:2:1 ratio to receive OnabotA X [REDACTED] [REDACTED] or [REDACTED] placebo [REDACTED]. Randomization will be stratified at each investigator site by baseline investigator-rated AGLSS at maximum contraction, using central by block stratified randomization. The same block will not be shared across investigative sites or by baseline GL severity assessment. AbbVie will provide instructions for [REDACTED] preparations and treatment administration separately, in the pharmacy manual.

2.4**Sample Size Determination**

The sample size was chosen empirically. [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]



3.0 Endpoints

3.1 Primary Endpoint(s)

The primary efficacy endpoint is achievement of \geq 1-grade improvement from baseline on the Allergan Glabellar Line Severity Scale (AGLSS) according to investigator assessments at maximum contraction at Day 30.

3.2 Secondary Endpoint(s)

- Achievement of None or Mild on the investigator-rated AGLSS assessments at maximum contraction at Day 30;

3.3 Other Efficacy Endpoint(s)



A series of 14 horizontal black bars of varying lengths, decreasing in size from top to bottom. The bars are set against a white background.

A series of nine horizontal black bars of varying lengths, decreasing from left to right. The bars are positioned at different vertical intervals, creating a stepped effect. The first bar is the longest and is positioned at the top. Subsequent bars are progressively shorter and are positioned lower down, with the ninth bar being the shortest and positioned at the bottom. The bars are set against a white background.

3.4 Safety Endpoint(s)

The safety endpoints for this study include:

- Adverse Events
- Abbreviated Physical Examination (general appearance, head, ears, eyes, nose, throat, and neck)

- Clinical Laboratory Test [REDACTED]
- Vital Sign Measurements [REDACTED]
[REDACTED]
- Electrocardiogram [REDACTED]
[REDACTED]
- Neurologic Assessment

3.5 Additional Endpoint(s)

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

4.0 Analysis Populations

The following population sets will be used for the analyses.

The Intent to Treat (ITT) Population includes all randomized subjects. The ITT Population will be used for all efficacy analyses. [REDACTED]

[REDACTED]

The Safety Analysis Set consists of all subjects who received at least 1 dose of study drug. The safety analyses will be based on the safety population. [REDACTED]

[REDACTED]

5.0 Subject Disposition

The total number of subjects who were screened, enrolled, and treated will be summarized. Reasons for exclusion, including screen failure, will be summarized.



For end of study participation, the number and percentage of subjects who completed the protocol defined follow-up period (or did not with associated reasons) will be summarized overall and by treatment group.

6.0 Study Drug Duration and Compliance

Duration of exposure will be summarized with descriptive statistics (mean and standard deviation, median, Q1, Q3, minimum, and maximum). The number of subjects exposed for specific period of time



will also be summarized. Duration of exposure will be calculated as date of study exit minus date of study drug administration +1.

7.0 Demographics, Baseline Characteristics, Medical History, and Prior/Concomitant Medications

Demographics, baseline characteristics, medical history, prior and concomitant medications, and concurrent procedure will be summarized overall and by treatment group for the ITT Population.



[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

7.1 Demographics and Baseline Characteristics

Continuous demographic variables include age. Categorical demographic variables include sex, ethnicity, race, age group [REDACTED].

Baseline characteristics include weight, height, body mass index (BMI), Fitzpatrick skin type, investigator-rated and subject-rated AGLSS severity at maximum contraction and at rest, baseline Facial Line Satisfaction Questionnaire (FLSQ[©]) impact domain score,

[REDACTED]

[REDACTED]

[REDACTED]

7.2 Medical History

Medical history data will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

7.3 Prior and Concomitant Medications

Prior and concomitant medications will be summarized by generic name. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] The number and percentage of subjects taking medications will be summarized by generic drug name based on the World Health Organization (WHO) Drug Dictionary for both prior and concomitant medications.

7.4 Concurrent Procedure

All procedures undergone on or after Study Day 1 visit through the exit visit will be considered concurrent procedures. Concurrent procedure will be summarized by MedDRA high level term and preferred term. [REDACTED]

[REDACTED]

[REDACTED]

8.0 Handling of Potential Intercurrent Events for the Primary and Key Secondary Endpoints

The primary endpoint and secondary endpoints will be analyzed based on the ITT population, [REDACTED]

- Subjects who are missing data for any other reason for the endpoint will count as though they hypothetically continued in the study.

9.0 Efficacy Analyses

9.1 General Considerations

All efficacy analyses will be conducted in the ITT Population in each period. [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED] All efficacy results will be summarized by treatment group.

Unless otherwise specified, any subject who is randomized based on a wrong stratum will be analyzed according to the actual stratum the subject belongs to.

"Baseline" refers to the last non-missing observation before the first administration of study drug or randomization if no study drug is given.

9.2 Handling of Missing Data

Missing data will be imputed using multiple imputation (MI) method for the primary and secondary endpoints.

[REDACTED]


[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]



Each of the 5 imputation data sets will be analyzed individually, then combined to generate the final inferences as described in Section 9.3.2.

9.3 Primary Efficacy Endpoint(s) and Analyses

9.3.1 Primary Efficacy Endpoint(s)

The primary efficacy endpoint is achievement of ≥ 1 -grade improvement from baseline on the investigator-based AGLSS at maximum contraction at Day 30.

9.3.2 Main Analysis of Primary Efficacy Endpoint(s)

The attributes of the estimands corresponding to the primary efficacy endpoint are summarized in Table 1.

Table 1. Summary of the Estimand Attributes of the Primary Efficacy Endpoint

Estimand Label	Attributes of the Estimand				
	Treatment	Endpoint	Population	Handling of Intercurrent Events	Statistical Summary
Hypothetical estimand for primary endpoint	OnabotA X or placebo	Achievement of ≥ 1 -grade improvement from baseline on the AGLSS according to investigator assessments at maximum contraction at Day 30	ITT (All randomized)	Subjects who discontinue study prior to Day 30 assessments, or who do not have AGLSS assessments will be included in the analysis as a hypothetical scenario in which they had not missed the AGLSS assessments	Difference in response proportions between each active treatment group and placebo, after MI using CMH test stratified by baseline investigator-rated AGLSS at maximum contraction

AGLSS = Allergan Glabellar Line Severity Scale; CMH = Cochran-Mantel-Haenszel; ITT = intent-to-treat; MI = multiple imputation; OnabotA X = onabotulinumtoxinA X

The evaluation of the equality of the proportions of responders will be based on Cochran-Mantel-Haenszel (CMH) test stratified by baseline investigator-rated AGLSS at maximum contraction. Wald confidence intervals for proportions of responders and difference in the proportion of responders will be presented. The Breslow-Day homogeneity of the odds-

ratio test will be performed to test the treatment-by-investigator-rated baseline GL severity at maximum contraction interaction.

To obtain pooled CMH p-value, the Wilson-Hilferty transformation will be used.^{1,2}



9.3.3 Sensitivity and Supplementary Analyses of the Primary Efficacy Endpoint(s)

A sensitivity analysis will be performed for the primary efficacy variable using observed data.

9.4 Secondary Efficacy Endpoints and Analyses

9.4.1 Key Secondary Efficacy Endpoints

The key secondary endpoints, which utilize both the AGLSS and FLSQ, include:

- Achievement of None or Mild on the investigator-rated AGLSS assessments at maximum contraction at Day 30;
- Responses of Very satisfied or Mostly satisfied on satisfaction with treatment per the FLSQ follow-up version Item 5 at Day 60;
- Achievement of \geq 14-point psychosocial impact improvement from baseline at Day 30 per the FLSQ Impact domain, among subjects with baseline scores \geq 14 points

9.4.2**Main Analyses of Key Secondary Efficacy Endpoints**

The attributes of the estimands corresponding to the secondary efficacy endpoints are summarized in Table 2.

Table 2. Summary of the Estimand Attributes of the Secondary Efficacy Endpoints

Attributes of the Estimand					
Estimand Label	Treatment	Endpoint	Population	Handling of Intercurrent Events	Statistical Summary
Hypothetical estimand for secondary endpoint	OnabotA X or placebo	Achievement of None or Mild on the investigator-rated AGLSS assessments at maximum contraction at Day 30	ITT (All randomized)	Subjects who discontinue study prior to Day 30 assessments, or who do not have AGLSS assessments will be included in the analysis as a hypothetical scenario in which they had not missed the AGLSS assessments	Difference in response proportions between each active treatment group and placebo, after MI using CMH test stratified by baseline investigator-rated AGLSS at maximum contraction
		Responses of Very satisfied or Mostly satisfied on satisfaction with treatment per the FLSQ follow-up version Item 5 at Day 60		Subjects who discontinue study prior to Day 60 assessments, or who do not have FLSQ assessments will be included in the analysis as a hypothetical scenario in which they had not missed the FLSQ assessments	
		Achievement of ≥ 14 -point psychosocial impact improvement from baseline at Day 30 per the FLSQ Impact domain, among subjects with baseline scores ≥ 14 points		Subjects who discontinue study prior to Day 30 assessments, or who do not have FLSQ assessments will be included in the analysis as a hypothetical scenario in which they had not missed the FLSQ assessments	

AGLSS = Allergan Glabellar Line Severity Scale; CMH = Cochran-Mantel-Haenszel; ITT = intent-to-treat; MI = multiple imputation; OnabotA X = onabotulinumtoxinA X

The key secondary efficacy endpoints are to be analyzed similarly to the primary endpoint using multiple imputation, as specified in Section 9.2. [REDACTED]

9.4.3 Sensitivity and Supplementary Analyses for Key Secondary Efficacy Endpoints

Not applicable.

9.4.4 Supportive Secondary Efficacy Endpoints and Analyses

Not applicable.

9.5 Additional Efficacy Analyses

A series of 12 horizontal black bars of varying lengths, decreasing from left to right. The bars are positioned against a white background and are evenly spaced vertically.



9.6 Efficacy Subgroup Analyses

Not applicable.

10.0 Safety Analyses

10.1 General Considerations


Safety data will be summarized for the Safety Analysis Set. For the safety analyses, subjects are summarized based on the treatment actually received.

10.2 Adverse Events

Adverse events (AEs) will be summarized overall and by treatment group and presented using primary MedDRA System Organ Classes (SOCs) and preferred terms (PTs) according to the version of the MedDRA coding dictionary used for the study at the time of database lock.



10.2.1 Treatment-Emergent Adverse Events



All treatment-emergent AEs will be summarized overall, as well as by primary MedDRA SOC and Preferred Term.

10.2.2 Adverse Event Overview


An overview of AEs will be presented consisting of the number and percentage of subjects experiencing at least one event for each of the following AE categories:

- Any treatment-emergent AE
- Any treatment-emergent AE related to study treatment according to the investigator



- Any PDSOT TEAEs
- All deaths

10.2.3 Treatment-Emergent Adverse Events by SOC and/or PT

Treatment-emergent AEs will be summarized by system organ class (SOC) and PT; by maximum severity and SOC and PT; and by subject number and SOC and PT. 



A horizontal bar chart with six bars of varying lengths. The bars are black and set against a white background. The lengths of the bars decrease from left to right, with the longest bar on the far left and the shortest bar on the far right.

10.2.4 SAEs (Including Deaths) and Adverse Events Leading to Study Drug Discontinuation

SAEs (including deaths) will be summarized by SOC and PT and in listing format.


10.2.5 Potential Distant Spread of Toxin Adverse Events

To assess PDSOT, MedDRA preferred terms that may be associated with botulinum toxin effects have been identified (Appendix B). [REDACTED]

10.3 Analysis of Laboratory Data

The clinical laboratory tests defined in the protocol operations manual (e.g., hematology, clinical chemistry, and urinalysis) will be summarized by treatment group.

A horizontal bar chart consisting of five solid black bars of increasing length from left to right. The bars are separated by thin white spaces. The first bar is the shortest, and the fifth bar is the longest, extending almost to the right edge of the frame.



10.4 Analysis of Vital Signs

Vital sign measurements of systolic and diastolic blood pressure, pulse rate, respiratory rate, and body temperature will be summarized by treatment group.



Country	Percentage (approx.)
Argentina	95
Australia	95
Austria	95
Belgium	95
Brazil	95
Bulgaria	95
Chile	95
Costa Rica	95
Czech Republic	95
Denmark	95
Ecuador	95
El Salvador	95
Finland	95
France	95
Germany	95
Greece	95
Hungary	95
Iceland	95
Ireland	95
Italy	95
Japan	95
Jordan	95
Luxembourg	95
Malta	95
Mexico	95
Netherlands	95
Norway	95
Peru	95
Poland	95
Portugal	95
Romania	95
Russia	95
San Marino	95
Slovakia	95
Slovenia	95
Spain	95
Sweden	95
Switzerland	95
Turkey	95
United Kingdom	95
Uruguay	95
Venezuela	95
Zimbabwe	95
Argentina	90
Australia	90
Austria	90
Belgium	90
Brazil	90
Bulgaria	90
Chile	90
Costa Rica	90
Czech Republic	90
Denmark	90
Ecuador	90
El Salvador	90
Finland	90
France	90
Germany	90
Greece	90
Hungary	90
Iceland	90
Ireland	90
Italy	90
Japan	90
Jordan	90
Luxembourg	90
Malta	90
Mexico	90
Netherlands	90
Norway	90
Peru	90
Poland	90
Portugal	90
Romania	90
Russia	90
San Marino	90
Slovakia	90
Slovenia	90
Spain	90
Sweden	90
Switzerland	90
Turkey	90
United Kingdom	90
Uruguay	90
Venezuela	90
Zimbabwe	90
Argentina	85
Australia	85
Austria	85
Belgium	85
Brazil	85
Bulgaria	85
Chile	85
Costa Rica	85
Czech Republic	85
Denmark	85
Ecuador	85
El Salvador	85
Finland	85
France	85
Germany	85
Greece	85
Hungary	85
Iceland	85
Ireland	85
Italy	85
Japan	85
Jordan	85
Luxembourg	85
Malta	85
Mexico	85
Netherlands	85
Norway	85
Peru	85
Poland	85
Portugal	85
Romania	85
Russia	85
San Marino	85
Slovakia	85
Slovenia	85
Spain	85
Sweden	85
Switzerland	85
Turkey	85
United Kingdom	85
Uruguay	85
Venezuela	85
Zimbabwe	85
Argentina	80
Australia	80
Austria	80
Belgium	80
Brazil	80
Bulgaria	80
Chile	80
Costa Rica	80
Czech Republic	80
Denmark	80
Ecuador	80
El Salvador	80
Finland	80
France	80
Germany	80
Greece	80
Hungary	80
Iceland	80
Ireland	80
Italy	80
Japan	80
Jordan	80
Luxembourg	80
Malta	80
Mexico	80
Netherlands	80
Norway	80
Peru	80
Poland	80
Portugal	80
Romania	80
Russia	80
San Marino	80
Slovakia	80
Slovenia	80
Spain	80
Sweden	80
Switzerland	80
Turkey	80
United Kingdom	80
Uruguay	80
Venezuela	80
Zimbabwe	80
Argentina	75
Australia	75
Austria	75
Belgium	75
Brazil	75
Bulgaria	75
Chile	75
Costa Rica	75
Czech Republic	75
Denmark	75
Ecuador	75
El Salvador	75
Finland	75
France	75
Germany	75
Greece	75
Hungary	75
Iceland	75
Ireland	75
Italy	75
Japan	75
Jordan	75
Luxembourg	75
Malta	75
Mexico	75
Netherlands	75
Norway	75
Peru	75
Poland	75
Portugal	75
Romania	75
Russia	75
San Marino	75
Slovakia	75
Slovenia	75
Spain	75
Sweden	75
Switzerland	75
Turkey	75
United Kingdom	75
Uruguay	75
Venezuela	75
Zimbabwe	75
Argentina	70
Australia	70
Austria	70
Belgium	70
Brazil	70
Bulgaria	70
Chile	70
Costa Rica	70
Czech Republic	70
Denmark	70
Ecuador	70
El Salvador	70
Finland	70
France	70
Germany	70
Greece	70
Hungary	70
Iceland	70
Ireland	70
Italy	70
Japan	70
Jordan	70
Luxembourg	70
Malta	70
Mexico	70
Netherlands	70
Norway	70
Peru	70
Poland	70
Portugal	70
Romania	70
Russia	70
San Marino	70
Slovakia	70
Slovenia	70
Spain	70
Sweden	70
Switzerland	70
Turkey	70
United Kingdom	70
Uruguay	70
Venezuela	70
Zimbabwe	70
Argentina	65
Australia	65
Austria	65
Belgium	65
Brazil	65
Bulgaria	65
Chile	65
Costa Rica	65
Czech Republic	65
Denmark	65
Ecuador	65
El Salvador	65
Finland	65
France	65
Germany	65
Greece	65
Hungary	65
Iceland	65
Ireland	65
Italy	65
Japan	65
Jordan	65
Luxembourg	65
Malta	65
Mexico	65
Netherlands	65
Norway	65
Peru	65
Poland	65
Portugal	65
Romania	65
Russia	65
San Marino	65
Slovakia	65
Slovenia	65
Spain	65
Sweden	65
Switzerland	65
Turkey	65
United Kingdom	65
Uruguay	65
Venezuela	65
Zimbabwe	65
Argentina	60
Australia	60
Austria	60
Belgium	60
Brazil	60
Bulgaria	60
Chile	60
Costa Rica	60
Czech Republic	60
Denmark	60
Ecuador	60
El Salvador	60
Finland	60
France	60
Germany	60
Greece	60
Hungary	60
Iceland	60
Ireland	60
Italy	60
Japan	60
Jordan	60
Luxembourg	60
Malta	60
Mexico	60
Netherlands	60
Norway	60
Peru	60
Poland	60
Portugal	60
Romania	60
Russia	60
San Marino	60
Slovakia	60
Slovenia	60
Spain	60
Sweden	60
Switzerland	60
Turkey	60
United Kingdom	60
Uruguay	60
Venezuela	60
Zimbabwe	60
Argentina	55
Australia	55
Austria	55
Belgium	55
Brazil	55
Bulgaria	55
Chile	55
Costa Rica	55
Czech Republic	55
Denmark	55
Ecuador	55
El Salvador	55
Finland	55
France	55
Germany	55
Greece	55
Hungary	55
Iceland	55
Ireland	55
Italy	55
Japan	55
Jordan	55
Luxembourg	55
Malta	55
Mexico	55
Netherlands	55
Norway	55
Peru	55
Poland	55
Portugal	55
Romania	55
Russia	55
San Marino	55
Slovakia	55
Slovenia	55
Spain	55
Sweden	55
Switzerland	55
Turkey	55
United Kingdom	55
Uruguay	55
Venezuela	55
Zimbabwe	55
Argentina	50
Australia	50
Austria	50
Belgium	50
Brazil	50
Bulgaria	50
Chile	50
Costa Rica	50
Czech Republic	50
Denmark	50
Ecuador	50
El Salvador	50
Finland	50
France	50
Germany	50
Greece	50
Hungary	50
Iceland	50
Ireland	50
Italy	50
Japan	50
Jordan	50
Luxembourg	50
Malta	50
Mexico	50
Netherlands	50
Norway	50
Peru	50
Poland	50
Portugal	50
Romania	50
Russia	50
San Marino	50
Slovakia	50
Slovenia	50
Spain	50
Sweden	50
Switzerland	50
Turkey	50
United Kingdom	50
Uruguay	50
Venezuela	50
Zimbabwe	50
Argentina	45
Australia	45
Austria	45
Belgium	45
Brazil	45
Bulgaria	45
Chile	45
Costa Rica	45
Czech Republic	45
Denmark	45
Ecuador	45
El Salvador	45
Finland	45
France	45
Germany	45
Greece	45
Hungary	45
Iceland	45
Ireland	45
Italy	45
Japan	45
Jordan	45
Luxembourg	45
Malta	45
Mexico	45
Netherlands	45
Norway	45
Peru	45
Poland	45
Portugal	45
Romania	45
Russia	45
San Marino	45
Slovakia	45
Slovenia	45
Spain	45
Sweden	45
Switzerland	45
Turkey	45
United Kingdom	45
Uruguay	45
Venezuela	45
Zimbabwe	45
Argentina	40
Australia	40
Austria	40
Belgium	40
Brazil	40
Bulgaria	40
Chile	40
Costa Rica	40
Czech Republic	40
Denmark	40
Ecuador	40
El Salvador	40
Finland	40
France	40
Germany	40
Greece	40
Hungary	40
Iceland	40
Ireland	40
Italy	40
Japan	40
Jordan	40
Luxembourg	40
Malta	40
Mexico	40
Netherlands	40
Norway	40
Peru	40
Poland	40
Portugal	40
Romania	40
Russia	40
San Marino	40
Slovakia	40
Slovenia	40
Spain	40
Sweden	40
Switzerland	40
Turkey	40
United Kingdom	40
Uruguay	40
Venezuela	40
Zimbabwe	40
Argentina	35
Australia	35
Austria	35
Belgium	35
Brazil	35
Bulgaria	35
Chile	35
Costa Rica	35
Czech Republic	35
Denmark	35
Ecuador	35
El Salvador	35
Finland	35
France	35
Germany	35
Greece	35
Hungary	35
Iceland	35
Ireland	35
Italy	35
Japan	35
Jordan	35
Luxembourg	35
Malta	35
Mexico	35
Netherlands	35
Norway	35
Peru	35
Poland	35
Portugal	35
Romania	35
Russia	35
San Marino	35
Slovakia	35
Slovenia	35
Spain	35
Sweden	35
Switzerland	35
Turkey	35
United Kingdom	35
Uruguay	35
Venezuela	35
Zimbabwe	35
Argentina	30
Australia	30
Austria	30
Belgium	30
Brazil	30
Bulgaria	30
Chile	30
Costa Rica	30
Czech Republic	30
Denmark	30
Ecuador	30
El Salvador	30
Finland	30
France	30
Germany	30
Greece	30
Hungary	30
Iceland	30
Ireland	30
Italy	30
Japan	30
Jordan	30
Luxembourg	30
Malta	30
Mexico	30
Netherlands	30
Norway	30
Peru	30
Poland	30
Portugal	30
Romania	30
Russia	30
San Marino	30
Slovakia	30
Slovenia	30
Spain	30
Sweden	30
Switzerland	30
Turkey	30
United Kingdom	30
Uruguay	30
Venezuela	30
Zimbabwe	30
Argentina	25
Australia	25
Austria	25
Belgium	25
Brazil	25
Bulgaria	25
Chile	25
Costa Rica	25
Czech Republic	25
Denmark	25
Ecuador	25
El Salvador	25
Finland	25
France	25
Germany	25
Greece	25
Hungary	25
Iceland	25
Ireland	25
Italy	25
Japan	25
Jordan	25
Luxembourg	25
Malta	25
Mexico	25
Netherlands	25
Norway	25
Peru	25
Poland	25
Portugal	25
Romania	25
Russia	25
San Marino	25
Slovakia	25
Slovenia	25
Spain	25
Sweden	25
Switzerland	25
Turkey	25
United Kingdom	25
Uruguay	25
Venezuela	25
Zimbabwe	25
Argentina	20
Australia	20
Austria	20
Belgium	20
Brazil	20
Bulgaria	20
Chile	20
Costa Rica	20
Czech Republic	20
Denmark	20
Ecuador	20
El Salvador	20
Finland	20
France	20
Germany	20
Greece	20
Hungary	20
Iceland	20
Ireland	20
Italy	20
Japan	20
Jordan	20
Luxembourg	20
Malta	20
Mexico	20
Netherlands	20
Norway	20
Peru	20
Poland	20
Portugal	20
Romania	20
Russia	20
San Marino	20
Slovakia	20
Slovenia	20
Spain	20
Sweden	20
Switzerland	20
Turkey	20
United Kingdom	20
Uruguay	20
Venezuela	20
Zimbabwe	20
Argentina	15
Australia	15
Austria	

10.5 Safety Subgroup Analyses

Not applicable.

10.6 Other Safety Analyses

Electrocardiogram (ECG):

A thick black horizontal bar, likely a redacted section of a document.

[REDACTED]

[REDACTED]

[REDACTED]

Neurologic Assessment: [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

11.0 Other Analyses

Immunogenicity: Blood samples for immunogenicity testing will be collected from all subjects [REDACTED]

[REDACTED]

[REDACTED]

Hypersensitivity: Blood samples to be collected within 2 hours of suspected anaphylaxis or systemic hypersensitivity reaction. [REDACTED]

[REDACTED]

12.0 Interim Analyses

An interim analysis is planned to occur [REDACTED]

[REDACTED] If a dose recommendation cannot be made at this point, then a second interim analysis will be performed [REDACTED]

[REDACTED] The interim analyses will be comparative and will be unblinded to a group of AbbVie personnel who are not directly involved in ongoing day-to-day study conduct. [REDACTED]

[REDACTED] Further details are provided in DMC Charter.

The primary and secondary efficacy analyses will be performed for each interim analysis, as well as summaries of all safety variables.

12.1 Data Monitoring Committee

An independent DMC will be instituted to review interim safety and efficacy data to provide a dose recommendation for Phase 3. A DMC Charter will be finalized prior to study start. [REDACTED]

A thick black horizontal bar, likely a redacted section of a document.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

13.0 Overall Type-I Error Control

Analyses will be conducted using a gated hierarchical testing procedure to preserve a familywise Type I error rate of $\alpha=0.05$ for each OnabotA X group compared to placebo, separately.

A horizontal bar chart consisting of four solid black bars of increasing length from left to right. The bars are separated by small gaps and are set against a white background.

14.0 Version History

Table 3. SAP Version History Summary

Version	Date of Approval	Summary
1.0	19 August 2021	Initial version
2.0		<p>Section 2.1, added details for estimand</p> <p>Section 4.0, changed the safety analysis set to be analyzed per randomization due to the difficulty of determine the actual treatment</p> <p>Section 8.0, added details for handling potential intercurrent events</p> <p>Section 9.3.2 Table 1, updated column ‘Handling of Intercurrent Events’</p> <p>Section 9.4.2 added Table 2, the Summary of the Estimand Attributes of the Secondary Efficacy Endpoints</p> <p>Updated Table B-1 MedDRA preferred terms evaluated for PDSOT, removed the term “Extraocular muscles paresis”, added the term “Ophthalmoplegia”</p> <p>Updated Table C-1 Criteria for Potentially Clinically Important Clinical Laboratory Values: updated the value corresponding to Cholesterol, Glucose, and Triglycerides. Changed “Inorganic phosphorus” to “Phosphate”</p>

15.0 References

1. EB W, MM H. The distribution of chi-square. Proc Natl Acad Sci U S A. 1931;17(12):684-8.
2. O'Kelly M, Ratitch B. Clinical trials with missing data: a guide for practitioners. First ed: John Wiley & Sons, Ltd; 2014.

Appendix A. Protocol Deviations

The number and percentage of unique subjects reporting significant protocol deviations will be summarized in total and by treatment group for all randomized or treated subjects. The number and percentage of unique subjects with protocol deviation categories below will also be summarized in total and by treatment group.

- Subject entered into the study even though s/he did not satisfy entry criteria.
- Subject received wrong treatment or incorrect dose of study.
- Subject took prohibited concomitant medication or concurrent procedure.

Appendix B. Definition of Possible Distant Spread of Toxin

Table B-1. MedDRA Preferred Terms Evaluated for PDSOT

Accommodation disorder	Hyporeflexia
Aspiration	Hypotonia
Bell's Palsy	Ileus paralytic
Botulism	Muscular weakness
Bradycardia	Ophthalmoplegia
Bulbar palsy	Paralysis
Constipation	Paresis cranial nerve
Cranial nerve palsies multiple	Pelvic floor muscle weakness
Cranial nerve paralysis	Peripheral nerve palsy
Diaphragmatic paralysis	Peripheral paralysis
Diplopia	Pneumonia aspiration
Dry mouth	Pupillary reflex impaired
Dysarthria	Respiratory arrest
Dysphagia	Respiratory depression
Dysphonia	Respiratory failure
Dyspnoea	Speech disorder
Eyelid function disorder	Urinary retention
Eyelid ptosis	Vision blurred
Facial paralysis	Vocal cord paralysis
Facial paresis	Vocal cord paresis

Note: Table is based on MedDRA 25.0; the actual list used for analysis will be based on the MedDRA version in use at the time of database lock.

Appendix C. Potentially Clinically Important Criteria for Safety Endpoints

